In humans, LL-37 has been associated with psoriasis, systemic lupus erythematosus, arthritis and atherosclerosis, whereas studies in murine models have shown that CRAMP influences disease processes such as atherosclerosis and autoimmune diabetes [36–42]. Here, CAMP is linked to systemic lupus erythematosus.